Skip to main content
OpenTrials

Clinical trial condition

CLDN18.2-positive Adenocarcinoma of the Gastroesophageal Junction

Explore clinical trials studying CLDN18.2-positive Adenocarcinoma of the Gastroesophageal Junction. Study availability and eligibility vary by location and protocol.

3 public trials 0 recruiting studies
Refine in advanced search Browse all conditions

CLDN18.2-positive Adenocarcinoma of the Gastroesophageal Junction trial results

Completed

Efficacy and Safety of IMAB362 in Combination With the EOX Regimen for CLDN18.2-positive Gastric Cancer

NCT01630083

Conditions
CLDN18.2-positive Adenocarcinoma of Esophagus, CLDN18.2-positive Adenocarcinoma of the Gastroesophageal Junction, CLDN18.2-positive Gastric Adenocarcinoma
Locations
  • Site BUL004 Plovdiv, Bulgaria
  • Site BUL001 Sofia, Bulgaria
  • Site BUL003 Sofia, Bulgaria
  • Site BUL005 Sofia, Bulgaria
View all 48 locations
View Trial Details
Completed

Safety and Activity of IMAB362 in Combination With Zoledronic Acid and Interleukin-2 in CLDN18.2-positive Gastric Cancer

NCT01671774

Conditions
CLDN18.2-positive Adenocarcinoma of Esophagus, CLDN18.2-positive Adenocarcinoma of the Gastroesophageal Junction, CLDN18.2-positive Gastric Adenocarcinoma
Locations
  • Institut für Klinische Forschung, Krankenhaus Nordwest GmbH Frankfurt am Main, Hesse, Germany
  • BAG / Onkologische Schwerpunktpraxis Dresden, Saxony, Germany
  • Charité Universitätsmedizin Berlin - CVK, Med. Klinik m.S. Hämatologie und Onkologie Berlin, Germany
  • Freiburg University Medical Center, Department of Internal Medicine II, Gastroenterology and Hepatology Freiburg im Breisgau, Germany
View Trial Details

Related conditions